VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
VM Oncology, LLC
VM Oncology, LLC
National Institutes of Health Clinical Center (CC)
Incyte Corporation
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Incyte Corporation
A2 Biotherapeutics Inc.
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
University College, London